SITC Resource Library

On August 13, 2021, leading experts in cancer immunotherapy presented an overview of the publication "Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events" during a live webinar. The recorded webinar and presentation slides are available below.

Webinar Faculty:

• Co-moderator: Julie R. Brahmer, MD, MSc – Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (Expert Panel Chair)
  
• Co-moderator: Marc S. Ernstoff, MD – National Institutes of Health (Expert Panel Chair)
• Gregory A. Masters, MD, FACP, FASCO – Helen F. Graham Cancer Center (Expert Panel Member)
  
• Paolo A. Ascierto, MD – Instituto Nazionale Tumori IRCCS, Fondazione 'G. Pascale' (Expert Panel Member)
• Igor Puzanov, MD, MSCI, FACP – Roswell Park Comprehensive Cancer Center (Expert Panel Member)

• SITC's cancer immunotherapy guidelines on immune checkpoint inhibitor-related adverse events
• Properly monitoring patients receiving immune checkpoint inhibitor therapies for treatment-related adverse events and identifying those at high risk
• Identifying common and uncommon toxicities that may occur with immune checkpoint inhibitor therapies
• Determining appropriate management techniques for common adverse events resulting from immune checkpoint inhibitor therapies

Disclaimer: Due to the rapidly-evolving field of cancer immunotherapy, some of the content on this page may be out of date. For current information from SITC on cancer immunotherapy, please visit connected.sitcancer.org.